Spectral expands EAA(TM) placement in leading European hospitals

TORONTO, Nov. 30 /CNW/ - Spectral Diagnostics Inc. (TSX: SDI) today
announced the placement of its proprietary sepsis diagnostics system, the
Endotoxin Activity Assay (EAA(TM)) at the Klinikum Grosshadern, of the
Ludwig-Maximillians University of Munich. The clinical usage of the assay will
be directed by Dr. Eugen Faist, Professor of Surgery.

Professor Faist is a recognized world leader in the areas of Sepsis and
Trauma. He will be the Congress Chairman for the 7th World Congress on Trauma,
Shock, Inflammation and Sepsis to be held in Munich, Germany in March 2007,
where further studies on the clinical utility of the EAA(TM) will be presented
by speakers from around the world.

"This placement is another significant step in the commercialization of
Spectral's EAA(TM) assay" stated Dr. Paul Walker, President and CEO of
Spectral. "We are very pleased to be working with Dr. Faist because of his
extensive experience and solid reputation in the area of sepsis and critical
care".

"We are pleased to have the EAA(TM) installed in our hospital. In
combination with other biomarkers, the EAA(TM) offers a new light on the
horizon to identify patients and facilitate timely clinical diagnosis", added
Dr. Faist.

Spectral continues to establish the EAA(TM) assay in leading hospitals
with world renowned clinicians. Two more significant sites in Paris, France
and Brussels, Belgium are scheduled for installation this quarter. These
placements are key with respect to the ongoing support of our commercial
distributors and their marketing efforts in Europe.

Spectral is a developer of innovative technologies for rapid diagnostics
in areas where accurate and timely information can make a significant impact
on patient outcomes. Information from Spectral products contributes to early
initiation of appropriate and targeted therapy. Current products include rapid
diagnostics for sepsis (EAA(TM)) and West Nile Virus as well as a range of
other biological reagents. Spectral's common shares are listed on The Toronto
Stock Exchange: SDI.

Information in this news release that is not current or historically
factual information may constitute forward-looking information within the
meaning of securities laws. Implicit in this information, the future outlook
of Spectral and anticipated events or results are assumptions based on beliefs
of Spectral's senior management as well as information currently available to
it. While these assumptions were considered reasonable by Spectral at the time
of preparation, they may prove to be incorrect. Readers are cautioned that
actual results are subject to a number of risks and uncertainties, including
the availability of funds and resources to pursue R&D projects, the successful
and timely completion of clinical studies, the ability of Spectral to take
advantage of business opportunities in the biomedical industry, the granting
of necessary approvals by regulatory authorities as well as general economic,
market and business conditions, and could differ materially from what is
currently expected.
%SEDAR: 00002006E